Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

AIDS

Volumn 25, Issue 18, 2011, Pages 2249-2258

  Gazzard, Brian ^a   Duvivier, Claudine ^b   Zagler, Christian ^c   Castagna, Antonella ^d   Hill, Andrew ^e   Van Delft, Yvonne ^f   Marks, Stephan ^f  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c OTTO WAGNER HOSPITAL   (Austria)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f NONE

Author keywords

antiretroviral treatment; drug resistance; HIV RNA; nonnucleoside reverse transcriptase inhibitors; nucleoside analogues

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGGRESSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; METABOLIC DISORDER; MOOD DISORDER; NEURALGIA; NEUROLOGIC DISEASE; NEUTROPENIA; NIGHTMARE; NUTRITIONAL DISORDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGICAL RESPONSE; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 80855130709     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834c4c06     Document Type: Article

References (37)

1. Thompson M, Aberg J, Cahn P, Montaner J, Rizzardini G, Telenti A, et al. Antiretroviral treatment of Adult HIV infection. 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
2. US Department for Health and Social Security. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 10 January 2011. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7 [Accessed March 2011]
3. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. http://www. europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV-Infected- Adults.pdf. [Accessed May 2011]
4. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263. (Pubitemid 38496486)
5. Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate release once daily in treatment-naive HIV-1 infected patients. Antivir Ther 2011; 16:759-769.
6. Perinatal HIV Guidelines Working Group. Public Health Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States-29 April 2009. http://www.emcureaidsinfo.com/pdf/ PerinatalGL-2009.pdf. [Accessed May 2011]
7. Munoz-Moreno J, Fumaz C, Ferrer M, Gonzalez-Garcia M, Molto J, Negredo E, Clotet B. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioural review. AIDS Rev 2009; 11:103-109.
8. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010; 12:67-75.
9. Hill A, Sawyer A, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10:1-12
10. US Food and Drug Administration. Efavirenz prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020972s035, 021360s023lbl.pdf. [Accessed May 2011]
11. Martinez E, Blanco JL, Arnaiz JA, Pérez-Cuevas J, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268. (Pubitemid 32592358)
12. Gupta R, Hill A, Sawyer A, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
13. The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
14. Riddler S, Haubrich R, DiRienzo G, Peeples L, Powderly W, Klingman K, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
15. Das K, Clark AD Jr, Lewi PJ, Heeres J, Jonge M, Koymans L, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47:2550-2560. (Pubitemid 38580092)
16. Andries K, AzijnH, Thielemans T, LudoviciD, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686. (Pubitemid 39577672)
17. Katlama C, Haubrich R, Lalezari R, Lazzarin A, Madruga J, Molina J, et al. Efficacy and safety of etravirine in treatmentexperienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
18. Gruzdev B, Rakhamanova A, Doubovaskaya E, Yakovlev A, Peeters M, Rinehart A. A randomized, double-blind, placebo controlled trial of TMC125 as 7-day monotherapy in antiretroviral na?̈ve, HIV-1 infected subjects. AIDS 2003; 17:2487-2494. (Pubitemid 38393321)
19. Lalezari J, DeJesus E, Osiyemi O, Ruane P, Haigney Z, Ryan R, et al. Pharmacokinetics of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-na?̈ve HIV-1 infected adults. Presented at the 9th International Conference on HIV Treatment; Glasgow, Scotland; November 2008; [abstract PO413].
20. Nelson M, Stellbrink H, Podzamczer D, Banhegyi D, Gazzard B, Hill A, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25:335-340.
21. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724. [Epub 2009 Mar 6]
22. DAIDS 2004. Division of AIDS table for grading the severity of adult and paediatric adverse events. http://rsc.tech-res.com/safetyandpharmacovigilance/. [Accessed April 2011]
23. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf. [Accessed April 2011]
24. Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment na?̈ve HIV-1 infected patients at week 48. AIDS 2008; 22:1389-1397.
25. Madruga J, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized, controlled Phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
26. Hill A, Sabin C. Designing and interpreting HIV noninferiority trials in na?̈ve and experienced patients. AIDS 2008; 22:913-921. (Pubitemid 351681499)
27. Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11:125-132.
28. Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D, et al. Safety and efficacy of raltegravir-based versus efavirenzbased combination therapy in treatment-na?̈ve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 2009; 374:796-806.
29. Eron J, Rockstroh J, Reynes J, Andrade-Villanueva J, Madruga J, Zhao J, et al. QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily raltegravir in combination therapy for treatment-naive HIV-infected patients. Presented at 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, USA; [abstract 150LB].
30. Peeters M, Vingerhoets J, Tambuyzer L, Azijn H, Hill A, De Meyer S. Etravirine limits the emergence of darunavir and other PI resistance-associated mutations in the DUET trials. AIDS 2010; 24:921-924.
31. Mackie N, Garvey L, Geretti A, Harrison L, Tilston P, Sabin C, et al. Predicting NNRTI resistance: do polymorphisms matter? Presented at 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, USA; [abstract 595].
32. Kakuda T, de Smedt G, Leemans R, Peeters M, Vyncke V, van Solingen-Ristea R, et al. Bioavailability of etravirine 200mg administered as a single 200-mg tablet versus two 100mg tablets in HIV-negative, healthy volunteers. Poster presented at the 6th IAS Conference on HIV pathogenesis, treatment and prevention; July 2011; Rome, Italy.
33. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires K, Meyer W, et al. Triple-nucleoside regimens versus efavirenzcontaining regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861. (Pubitemid 38917251)
34. Gutlerrez-Valencia A, Lopez-Cortes L, Vicana P, Palacios R, Ruiz-Valderas R, Lozano F, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events. Ann Int Med 2009; 151:1-9.
35. Waters L, Fisher M, Winston A, Higgs C, Hadley W, Garvey L, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011; 25:65-71.
36. Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Fayet-Mello A, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25:57-63.
37. Tibotec US Health Professional Letter, October 2009. http://i-base.info/ htb/6063. [Accessed May 2011]